These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 10353725)

  • 1. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
    Raul F
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
    Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible ototoxicity associated with difluoromethylornithine.
    Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
    Arbeit JM; Riley RR; Huey B; Porter C; Kelloff G; Lubet R; Ward JM; Pinkel D
    Cancer Res; 1999 Aug; 59(15):3610-20. PubMed ID: 10446971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-difluoromethylornithine inhibits N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in zinc-deficient rats: effects on esophageal cell proliferation and apoptosis.
    Fong LY; Pegg AE; Magee PN
    Cancer Res; 1998 Dec; 58(23):5380-8. PubMed ID: 9850069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
    Gerner EW; Meyskens FL; Goldschmid S; Lance P; Pelot D
    Amino Acids; 2007 Aug; 33(2):189-95. PubMed ID: 17396214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
    Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
    Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
    O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
    Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
    Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
    Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
    Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
    Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of oral carcinogenesis by DL-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats.
    Tanaka T; Kojima T; Hara A; Sawada H; Mori H
    Cancer Res; 1993 Feb; 53(4):772-6. PubMed ID: 8428357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine.
    Gerner EW; Garewal HS; Emerson SS; Sampliner RE
    Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):325-30. PubMed ID: 8061581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
    Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
    Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
    Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
    Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice.
    Sunkara PS; Rosenberger AL
    Cancer Res; 1987 Feb; 47(4):933-5. PubMed ID: 3100031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
    Xu H; Washington S; Verderame MF; Manni A
    Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.